CRISPR Therapeutics AG (CRSP) Common Equity (2015 - 2026)

CRISPR Therapeutics AG has disclosed Common Equity across 12 years of filings, most recently posting $1.7 billion for Q2 2026.

• In Q2 2026, Common Equity rose 2.07% year-over-year to $1.7 billion; the TTM figure through Jun 2026 stood at $1.7 billion (up 2.07% YoY), while the FY2025 annual figure was $1.9 billion, down 0.53% from the prior year.
• Common Equity came in at $1.7 billion for Q2 2026 at CRISPR Therapeutics AG, down from $1.8 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $2.2 billion in Q1 2022 to a low of $1.7 billion in Q2 2025.
• Average Common Equity over 5 years is $1.9 billion, with a median of $1.9 billion recorded in 2023.
• The largest YoY upside for Common Equity was 24.34% in 2022 against a maximum downside of 22.24% in 2022.
• Over 5 years, Common Equity stood at $1.9 billion in 2022, then advanced by 0.39% to $1.9 billion in 2023, then increased by 2.62% to $1.9 billion in 2024, then slipped by 0.53% to $1.9 billion in 2025, then fell by 9.12% to $1.7 billion in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $1.7 billion in Q2 2026, $1.8 billion in Q1 2026, and $1.9 billion in Q4 2025.